Myocardial Infarction Pipeline Analysis Featuring 50+ Key Companies by DelveInsight

DelveInsight's, "Myocardial Infarction Pipeline Insight, 2022," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Myocardial Infarction Pipeline Insight

• Over 50+ Myocardial Infarction pipeline therapies are in various stages of development, and their anticipated acceptance in the Myocardial Infarction market would significantly increase market revenue.
• Leading Myocardial Infarction companies developing novel drug candidates to improve the Myocardial Infarction treatment landscape include AstraZeneca, Mesoblast, Boehringer Ingelheim, PT. Prodia Stem Cell Indonesia, Honya Medical Inc, Ever Supreme Bio Technology, Bayer, Athera Biotechnologies, MedImmune, Polyphor Ltd., Idorsia Pharmaceuticals, R-Pharm, Faraday Pharmaceuticals, CSL Behring, Recardio, Inc., Helixmith, Quantum Genomics, CeleCor Therapeutics, Novartis, Shanghai Life Science & Technology, Dexa Medica Group, CellProthera, LG Life Sciences, Synokem Pharmaceuticals, Windtree Therapeutics, Quark Pharmaceuticals, Kancera, BioCardia, Actelion Pharmaceuticals, Capricor, Athersys, Bharat Biotech, Cynata Therapeutics, and others.
• Promising Myocardial Infarction Pipeline therapies in various stages of development include AMI MultiStem®, BioMonitor, RPH-104 80 mg, Metoprolol- Toprol XL, Metoprolol- Lopressor, AO Therapy (aqueous oxygen), Aliskiren, Vitalscan, and others.
• The Myocardial Infarction Companies and academics are working to assess challenges and seek opportunities that could influence Myocardial infarction R&D. The therapies under development are focused on novel approaches to treat/improve Myocardial infarction.

Request a sample and discover the recent breakthroughs happening in Myocardial Infarction pipeline landscape @ https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myocardial Infarction Overview

Myocardial Infarction (MI) is a term used for an event of heart attack which is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply. The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, sweating, nausea, vomiting, abnormal heart beating, anxiety, fatigue, weakness, stress, depression, and other factors. The immediate treatment of MI include, taking aspirin, which prevents blood from clotting, and nitro-glycerin to treat chest pain and oxygen. The heart attack can be prevented by taking an earlier action to lower those risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, drugs, monitoring of blood pressure every week, doing exercise every day, and loosing body weight. The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack.

Recent Developmental Activities in the Myocardial Infarction Pipeline
• In June 2021, Idorsia Ltd (SIX: IDIA) declared the commencement of the Phase 3 registration study "SOS-AMI" to assess the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
• Currently, ProSTEM collaborates with Cipto Mangunkusumo Hospital and Medistra to conduct a clinical trial, "Allogeneic Stem Cell Therapy from Cord Tissue for Acute Myocardial Infarction."
• Umbilical cord mesenchymal stem cells (UMC01) by Ever Supreme Bio Technology Co., Ltd., for treating acute myocardial infarction (AMI) Phase the FDA approved I clinical trial in February 2018, and by TFDA in September of the same year for entering clinical trials; an investigation new drug research for treating stroke by stem cells via intravenous injection (IV) was also approved by the FDA for Phase I clinical-go in September 2018. Also, the TFDA Phase I clinical-go in March of 2020.
• In March 2021, Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing a potentially life-changing critical illness, announced that it had reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the protocol design and statistical analysis approach to be taken in Faraday's Phase 3 cardiovascular outcomes study evaluating FDY-5301 for the treatment of acute ST-segment elevation myocardial infarction (STEMI) in patients undergoing percutaneous intervention (PCI).
• Dapansutrile (Olatec Therapeutics) has been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models, including arthritis, asthma, acute myocardial infarction (AMI), contact dermatitis, multiple sclerosis, melanoma and breast cancers, spinal cord injury (SCI) and Alzheimer's disease.
• ATH3G10 is a first-in-class fully human antibody to target phosphorylcholine (PC), the head group of oxidized phospholipids (oxPLs), an epitope on damaged or stressed cells. The candidate is initially being developed for patients with a large ST-elevation myocardial infarction (STEMI) who are at a high risk of heart failure.

Myocardial Infarction Emerging Drugs Profile
• Dapagliflozin: AstraZeneca
• Remestemcel-L: Mesoblast

For further information, refer to the detailed Myocardial Infarction Pipeline Therapeutics Report @ https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myocardial Infarction Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Myocardial Infarction. The companies which have their Myocardial Infarction drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Myocardial Infarction Segmentation
• By Phases
• By Route of Administration
• By Molecule Type

Dive deep into rich insights for Myocardial Infarction emerging therapies and assessment; visit Myocardial Infarction Emerging Therapies @ https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Myocardial Infarction Pipeline Report
• Coverage- Global
• Myocardial Infarction Companies- AstraZeneca, Mesoblast, Boehringer Ingelheim, PT. Prodia Stem Cell Indonesia, Honya Medical Inc, Ever Supreme Bio Technology, Bayer, Athera Biotechnologies, MedImmune, Polyphor Ltd., Idorsia Pharmaceuticals, R-Pharm, Faraday Pharmaceuticals, CSL Behring, Recardio, Inc., Helixmith, Quantum Genomics, CeleCor Therapeutics, Novartis, Shanghai Life Science & Technology, Dexa Medica Group, CellProthera, LG Life Sciences, Synokem Pharmaceuticals, Windtree Therapeutics, Quark Pharmaceuticals, Kancera, BioCardia, Actelion Pharmaceuticals, Capricor, Athersys, Bharat Biotech, Cynata Therapeutics, and others.
• Myocardial Infarction Pipeline therapies in various stages of development include AMI MultiStem®, BioMonitor, RPH-104 80 mg, Metoprolol- Toprol XL, Metoprolol- Lopressor, AO Therapy (aqueous oxygen), Aliskiren, Vitalscan, and others.
• Myocardial Infarction Emerging Therapies, Unmet Needs, Analyst Views

Table of Content
1. Introduction
2. Myocardial Infarction Executive Summary
3. Myocardial Infarction: Overview
4. Myocardial Infarction Pipeline Therapeutics
5. Myocardial Infarction Therapeutic Assessment
6. Myocardial Infarction - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Myocardial Infarction Collaboration Deals
9. Late Stage Products (Phase III)
10. Dapagliflozin: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Remestemcel-L: Mesoblast
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Myocardial Infarction Key Companies
17. Myocardial Infarction Key Products
18. Myocardial Infarction- Unmet Needs
19. Myocardial Infarction- Market Drivers and Barriers
20. Myocardial Infarction- Future Perspectives and Conclusion
21. Myocardial Infarction Analyst Views
22. Myocardial Infarction Key Companies
23. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Myocardial Infarction drugs?
• How many Myocardial Infarction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myocardial Infarction?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myocardial Infarction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myocardial Infarction and their status?
• What are the key designations that have been granted to the emerging drugs?

Visit to know more of what's covered, Myocardial Infarction Emerging Therapies, Treatments, and Ongoing Clinical Trials @ https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.